Clinical Trial Update: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 3]

View source ↗

Summary

A Phase 3 trial sponsored by Sanofi is evaluating isatuximab with bortezomib, lenalidomide and dexamethasone in adults with newly diagnosed multiple myeloma who…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Isatuximab (isatuximab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING